$366,000–$398,000/yr
US
Unlimited PTO
- Provide strategic leadership and medical expertise for clinical development of antibody portfolio in IBD.
- Lead ongoing Phase 2 platform study and shape registrational program.
- Drive cross-functional collaboration and regulatory interactions for global submissions.